Benzodiazepine-GABAA receptor binding is very low in dysembryoplastic neuroepithelial tumor:: a PET study

被引:19
|
作者
Richardson, MP [1 ]
Hammers, A [1 ]
Brooks, DJ [1 ]
Duncan, JS [1 ]
机构
[1] Epilepsy Res Grp, London WC1N 3BG, England
关键词
DNET; flumazenil; PET; epilepsy; GABA(A);
D O I
10.1046/j.1528-1157.2001.44100.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To determine the nature of abnormalities of gamma -aminobutyric acid (GABA)A-central benzodiazepine (BZD) receptor binding in patients with dysembryoplastic neuroepithelial tumor (DNET) in comparison with normal controls. Methods: Five patients with DNET and 24 normal controls underwent ((11)C)flumazenil positron emission tomography (PET) to measure ((11)C)flumazenil volume of distribution (FMZVD) at the voxel level. Patients were compared with normal controls by using statistical parametric mapping (SPM) and also a partial-volume effect (PVE) corrected volume-of-interest (VOI) analysis covering the entire brain. First, using SPM, the highest Z-score for the entire image representing FMZVD decreases in comparison with the normals was found. Second, regions of abnormal FMZVD were located using SPM, p < 0.001 uncorrected, corrected p < 0.05. Finally, PVE- corrected measures of FMZVD were calculated for each patient VOI and compared wih those of normals, using significance levels of >2.5 standard deviations (SD) for the DNET and >3 SD for all other regions. Results: In all cases, the highest Z-score across the whole image representing decreased FMZVD was within the DNET. In three cases SPM revealed a single region of significantly reduced FMZVD, within the DNET in all three. VOI analysis showed PVE-corrected FMZVD was significantly low in the DNET in four cases. VOI analysis also showed seven other regions of abnormal FMZVD; three were adjacent to a DNET, and two were in mesial temporal areas not affected by DNET. Conclusions: FMZVD is low in DNET, probably contributing to epileptogenicity.
引用
收藏
页码:1327 / 1334
页数:8
相关论文
共 50 条
  • [41] STRIATAL D-1 AND D-2 RECEPTOR-BINDING IN PATIENTS WITH HUNTINGTONS-DISEASE AND OTHER CHOREAS - A PET STUDY
    TURJANSKI, N
    WEEKS, R
    DOLAN, R
    HARDING, AE
    BROOKS, DJ
    BRAIN, 1995, 118 : 689 - 696
  • [42] 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy:: an [18F]MPPF-PET study
    Merlet, I
    Ostrowsky, K
    Costes, N
    Ryvlin, P
    Isnard, J
    Faillenot, I
    Lavenne, F
    Dufournel, D
    Le Bars, D
    Mauguière, F
    BRAIN, 2004, 127 : 900 - 913
  • [43] Mass dose effects and in vivo affinity in brain PET receptor studies - a study of cerebral 5-HT4 receptor binding with [11C]SB207145
    Madsen, Karine
    Marner, Lisbeth
    Haahr, Mette
    Gillings, Nic
    Knudsen, Gitte M.
    NUCLEAR MEDICINE AND BIOLOGY, 2011, 38 (08) : 1085 - 1091
  • [44] Relation of dopamine receptor 2 binding to pain perception in female fibromyalgia patients with and without depression - A [11C] raclopride PET-study
    Ledermann, K.
    Jenewein, J.
    Sprott, H.
    Hasler, G.
    Schnyder, U.
    Warnock, G.
    Johayem, A.
    Kollias, S.
    Buck, A.
    Martin-Soelch, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (02) : 320 - 330
  • [45] Central 5-HT4 Receptor Binding as Biomarker of Serotonergic Tonus in Humans: A [11C]SB207145 PET Study
    Haahr, Mette
    Fisher, Patrick
    Gaden, Christian
    Frokjaer, Vibe
    McMahon, Brenda
    Madsen, Karine
    Baare, Wim
    Lehel, Szabolz
    Norremolle, Anne
    Rabiner, Eugenii Alfredovich.
    Knudsen, Gitte M.
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S240 - S241
  • [46] Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study
    M E Haahr
    P M Fisher
    C G Jensen
    V G Frokjaer
    B Mc Mahon
    K Madsen
    W F C Baaré
    S Lehel
    A Norremolle
    E A Rabiner
    G M Knudsen
    Molecular Psychiatry, 2014, 19 : 427 - 432
  • [47] Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study
    Haahr, M. E.
    Fisher, P. M.
    Jensen, C. G.
    Frokjaer, V. G.
    Mc Mahon, B.
    Madsen, K.
    Baare, W. F. C.
    Lehel, S.
    Norremolle, A.
    Rabiner, E. A.
    Knudsen, G. M.
    MOLECULAR PSYCHIATRY, 2014, 19 (04) : 427 - 432
  • [48] Higher Pretreatment 5-HT1A Receptor Binding Potential in Bipolar Disorder Depression is Associated With Treatment Remission: A Naturalistic Treatment Pilot PET Study
    Lan, Martin J.
    Hesselgrave, Natalie
    Ciarleglio, Adam
    Ogden, R. Todd
    Sullivan, Gregory M.
    Mann, J. John
    Parsey, Ramin V.
    SYNAPSE, 2013, 67 (11) : 773 - 778
  • [49] STRIATAL OPIOID RECEPTOR-BINDING IN PARKINSONS-DISEASE, STRIATONIGRAL DEGENERATION AND STEELE-RICHARDSON-OLSZEWSKI SYNDROME - A [C-11] DIPRENORPHINE PET STUDY
    BURN, DJ
    RINNE, JO
    QUINN, NP
    LEES, AJ
    MARSDEN, CD
    BROOKS, DJ
    BRAIN, 1995, 118 : 951 - 958
  • [50] AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects
    Jucaite, Aurelija
    Takano, Akihiro
    Bostrom, Emma
    Jostell, Karl-Gustav
    Stenkrona, Per
    Halldin, Christer
    Segerdahl, Marta
    Nyberg, Svante
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2013, 16 (06) : 1231 - 1239